Full Breakdown
Oura Targets September 2026 U.S. Initial Public Offering (IPO) Valuing the Smart-Ring Maker at Over $16 Billion
8/25/2026, 8:22:30 PM
Core Event: Planned IPO and Valuation
Sources reported on August 24 that Oura Health, the Finnish maker of the sleep-tracking smart ring, is preparing a U.S. IPO as early as September 2026. The offering could raise up to $3 billion and would value the company at more than $16 billion—about 47 % above the $10.9 billion valuation recorded after its September-2024 Series E financing. Most shares are expected to be sold by existing investors, making the IPO partly a liquidity event for early backers.
Background & Context
Founded in 2013, Oura grew from a niche “bio-hacker” device to a mainstream wellness brand focused on sleep, stress and recovery. The company filed a confidential S-1 in May 2026 and employs more than 900 staff in San Francisco and Finland. Competition in wearables has intensified, with Samsung’s Galaxy Ring and Whoop’s band targeting similar health-monitoring use cases.
Data & Statistics
- Revenue growth: $500 million in 2024, projected $1 billion for 2025 and roughly $2 billion for 2026.
- Unit sales: About 2.5 million rings sold by June 2024; the CEO projects 5.5 million units by September 2025.
- Funding history: The September-2024 Series E round raised $875 million from investors including Fidelity, ICONIQ, Whale Rock, Atreides, Dexcom, The Chernin Group, Forerunner Ventures, Coatue and Temasek.
- Underwriters: Expected syndicate includes Goldman Sachs, Morgan Stanley, JPMorgan Chase, Allen & Co. and Jefferies.
Official Statements & Responses
A company spokesperson told reporters that Oura will “defend” the pending lawsuit in the appropriate legal forum and emphasized that, while Oura rings are not medical devices, the sleep-stage algorithm has been validated in independent studies and compares favorably with polysomnography.
Criticism & Opposition
On August 20, Clarkson Law Firm filed a proposed class-action lawsuit in San Francisco alleging that Oura misled consumers about the accuracy of its sleep-tracking features. The complaint says the ring claims to determine precise sleep stages—a capability that normally requires scalp electrodes and ocular sensors used in clinical sleep labs, and alleges the AI-generated estimates are no more reliable than random guessing.
Conflicting Reports & Gaps
Public disclosures have not revealed Oura’s exact subscription-revenue share or total membership numbers, leaving analysts unable to assess the recurring-revenue component that underpins the $16 billion valuation. The S-1 filing, expected before the September listing, is the primary source that could resolve this gap.
Why It Matters / Impact
The IPO would place a European hardware company among the largest U.S. tech listings of 2026, highlighting investor appetite for wellness-focused wearables. Valuation hinges on Oura’s ability to monetize data through subscriptions while navigating regulatory scrutiny over health-claim accuracy. A favorable legal outcome could reinforce confidence in the company’s scientific credibility; an adverse ruling might pressure the valuation and affect broader market perception of consumer-health wearables.
Timeline
- May 2026 – Confidential filing of U.S. IPO registration.
- August 24 – Sources disclose planned September listing and $16 billion valuation target.
- August 20 – Clarkson Law Firm files class-action lawsuit in San Francisco.
- September 2026 (target) – Anticipated IPO launch and share offering.
What’s Next
Investors will await the public release of Oura’s S-1 registration statement, which should detail revenue composition, subscription metrics and any regulatory filings. The company must also address the class-action lawsuit as the IPO process proceeds and demonstrate that its sleep-staging technology meets the accuracy standards cited in its public statements.
